Candel Therapeutics, Inc. CADL Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -51.2%+47.0pp | -64.6%+75.0pp | —— | —— | -98.1%+65.6pp | |
| Return on assets | -36.5%+25.7pp | -32.9%+41.6pp | -39.5%+106pp | -33.4%+83.9pp | -62.3%+13.6pp | |
| Liquidity | ||||||
| Current ratio | 28×+23.4× | 13.5×+10.7× | 8.2×+7.1× | 7×+5.4× | 4.6×+2.6× | |
| Quick ratio | 28×+23.4× | 13.5×+10.7× | 8.2×+7.1× | 7×+5.4× | 4.6×+2.6× | |
| Cash ratio | 27.6×+23.0× | 13.3×+10.6× | 8×+6.9× | 6.8×+5.3× | 4.6×+2.7× | |
| Leverage | ||||||
| Debt-to-equity | 0×-0.1× | 0.1×-0.1× | 0.1×— | 0.1×— | 0.1×-1.8× | |
| Debt-to-assets | 0×-0.1× | 0×-0.1× | 0.1×-0.5× | 0.1×-0.4× | 0.1×-0.3× | |
| Interest coverage | -16.7×+2.5× | -22.8×-6.8× | -37.2×-22.2× | -25.5×-11.6× | -19.2×-5.3× | |
| Per Share | ||||||
| Book value per share | $2.21+62.3% | $0.98-53.2% | $1.46+406% | $1.75+625% | $1.36+566% | |
| Valuation | ||||||
| Market capitalization | $693.87M+192% | $310.18M-19.7% | $279.97M+35.2% | $243M+34.2% | $266.88M+483% | |
| Enterprise value | $501.88M+220% | $193.36M-34.5% | $200.21M-1.0% | $150.65M-12.1% | $185.63M+480% | |
| Price / book | 5×+1.8× | 6×+0.2× | 3.5×— | 2.7×— | 3.6×-4.1× | |
| Free cash flow yield | -7.1%+4.4pp | -12.5%-5.5pp | -12.1%+1.8pp | -12.3%+4.8pp | -10.2%+60.1pp | |
| Earnings yield | -7.8%+8.8pp | -12.3%+2.0pp | -8.1%+17.1pp | -9.1%+18.5pp | -14.8%+66.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Candel Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Candel Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
